doi: 10.36349/easjacc.2020.v02i03.001 17 BanjacA.PerisicT.SatoH.SeilerA.BannaiS.WeissN.et al
Given that there is currently no drug to treat long COVID despite more than $1 billion in spending on research by the federal government, the possibility that GLP-1 drugs are beneficial in this domain is extremely appealing
Sharma SS, Dietz KJ
However, this single modality often proves insufficient for numerous patients, including those who might eventually become GLP-1 non-responders
Tang H, Lu Y, Okun MS, Donahoo WT, Ramirez-Zamora A, Wang F, Huang Y, Armstrong M, Svensson M, Virnig BA, DeKosky ST, Bian J, Guo J (2024) Glucagon-like Peptide-1 receptor agonists and risk of Parkinsons Disease in patients with type 2 diabetes: a Population-based Cohort Study
Moe, Robert S